» Articles » PMID: 33039464

High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids

Abstract

Background & Aims: Preclinical identification of compounds at risk of causing drug induced liver injury (DILI) remains a significant challenge in drug development, highlighting a need for a predictive human system to study complicated DILI mechanism and susceptibility to individual drug. Here, we established a human liver organoid (HLO)-based screening model for analyzing DILI pathology at organoid resolution.

Methods: We first developed a reproducible method to generate HLO from storable foregut progenitors from pluripotent stem cell (PSC) lines with reproducible bile transport function. The qRT-PCR and single cell RNA-seq determined hepatocyte transcriptomic state in cells of HLO relative to primary hepatocytes. Histological and ultrastructural analyses were performed to evaluate micro-anatomical architecture. HLO based drug-induced liver injury assays were transformed into a 384 well based high-speed live imaging platform.

Results: HLO, generated from 10 different pluripotent stem cell lines, contain polarized immature hepatocytes with bile canaliculi-like architecture, establishing the unidirectional bile acid transport pathway. Single cell RNA-seq profiling identified diverse and zonal hepatocytic populations that in part emulate primary adult hepatocytes. The accumulation of fluorescent bile acid into organoid was impaired by CRISPR-Cas9-based gene editing and transporter inhibitor treatment with BSEP. Furthermore, we successfully developed an organoid based assay with multiplexed readouts measuring viability, cholestatic and/or mitochondrial toxicity with high predictive values for 238 marketed drugs at 4 different concentrations (Sensitivity: 88.7%, Specificity: 88.9%). LoT positively predicts genomic predisposition (CYP2C9∗2) for Bosentan-induced cholestasis.

Conclusions: Liver organoid-based Toxicity screen (LoT) is a potential assay system for liver toxicology studies, facilitating compound optimization, mechanistic study, and precision medicine as well as drug screening applications.

Citing Articles

Cell-based approaches for the mechanistic understanding of drug-induced cholestatic liver injury.

Timor-Lopez E, Tolosa L, Donato M Arch Toxicol. 2025; .

PMID: 40064699 DOI: 10.1007/s00204-025-04016-0.


Current hPSC-derived liver organoids for toxicity testing: Cytochrome P450 enzymes and drug metabolism.

Kim H, Park H Toxicol Res. 2025; 41(2):105-121.

PMID: 40013078 PMC: 11850699. DOI: 10.1007/s43188-024-00275-8.


Organoid, organ-on-a-chip and traditional Chinese medicine.

Yang J, Jiang Y, Li M, Wu K, Wei S, Zhao Y Chin Med. 2025; 20(1):22.

PMID: 39940016 PMC: 11823035. DOI: 10.1186/s13020-025-01071-8.


Advances in liver organoids: replicating hepatic complexity for toxicity assessment and disease modeling.

Shao W, Xu H, Zeng K, Ye M, Pei R, Wang K Stem Cell Res Ther. 2025; 16(1):27.

PMID: 39865320 PMC: 11771052. DOI: 10.1186/s13287-025-04139-2.


Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.

Durazzo M, Ferro A, Navarro-Tableros V, Gaido A, Fornengo P, Altruda F Biomolecules. 2025; 15(1).

PMID: 39858515 PMC: 11763965. DOI: 10.3390/biom15010121.


References
1.
Aleo M, Luo Y, Swiss R, Bonin P, Potter D, Will Y . Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology. 2014; 60(3):1015-22. DOI: 10.1002/hep.27206. View

2.
Rachek L, Yuzefovych L, LeDoux S, Julie N, Wilson G . Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol. 2009; 240(3):348-54. PMC: 2767118. DOI: 10.1016/j.taap.2009.07.021. View

3.
Yang K, Woodhead J, Watkins P, Howell B, Brouwer K . Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther. 2014; 96(5):589-98. PMC: 4480860. DOI: 10.1038/clpt.2014.158. View

4.
Fisher A, Croft-Baker J, Davis M, Purcell P, McLean A . Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord. 2002; 17(6):1362-5; discussion 1397-1400. DOI: 10.1002/mds.10342. View

5.
Serviddio G, Pereda J, Pallardo F, Carretero J, Borras C, Cutrin J . Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology. 2004; 39(3):711-20. DOI: 10.1002/hep.20101. View